RT Journal Article
SR Electronic
T1 Data-driven analysis on the simulations of the spread of COVID-19 under different interventions of China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.15.20103051
DO 10.1101/2020.05.15.20103051
A1 Tian, Ting
A1 Zhang, Jingwen
A1 Lin, Shiyun
A1 Jiang, Yukang
A1 Tan, Jianbin
A1 Li, Zhongfei
A1 Wang, Xueqin
YR 2020
UL http://medrxiv.org/content/early/2020/07/01/2020.05.15.20103051.abstract
AB Since February 2020, COVID-19 has spread rapidly to more than 200 countries in the world. During the pandemic, local governments in China have implemented different interventions to efficiently control the spread of the epidemic. Characterizing transmission of COVID-19 under some typical interventions is essential to help countries develop appropriate interventions. Based on the pre-symptomatic transmission patterns of COVID-19, we established a novel compartmental model: Baysian SIHR model with latent Markov structure, which treated the numbers of infected and infectious individuals without isolation to be the latent variables and allowed the effective reproduction number to change over time, thus the effects of policies could be reasonably estimated. By using the epidemic data of Wuhan, Wenzhou and Shenzhen, we migrated the corresponding estimated policy modes to South Korea, Italy, and the United States and simulated the potential outcomes for these countries when they adopted similar policy strategies of three cities in China. We found that the mild interventions implemented in Shenzhen were effective to control the epidemic in the early stage, while more stringent policies which were issued in Wuhan and Wenzhou were necessary if the epidemic was more severe and needed to be controlled in a short time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe epidemic data were extracted for Wuhan, Wenzhou, and Shenzhen from the Chinese Center for Disease Control and Prevention (China CDC) (National Health Commission of the People's Republic of China, 2020), and the data for South Korea, Italy and the United States were downloaded through April 23, 2020 from COVID-19 Knowledge & Data Hub (Sciences, 2020). http://2019ncov.chinacdc.cn/2019-nCoV/index.html http://geodoi.ac.cn/covid-19/en/index.aspx